Spreading risk across a broad range of initiatives
Cellgen’s initial market position will be built on a management philosophy that maintains a sharp eye toward the future but understands the value of executing in the present. In this regard, Cellgen’s future viability is exceptionally robust. We will develop a broad portfolio of stand-alone diagnostics across a diverse set of autoimmune disease indications. These disease areas include Rheumatoid Arthritis, Lupus, Type I Diabetes, Chrohn’s Disease and Multiple Sclerosis, but are not limited to. In addition, there are over 300 FDA approved pharmacogenomics biomarkers on current drug labels that Cellgen can leverage.
As the diagram below indicates, the journey from diagnostic inception to actual product launch is both lengthy and uncertain. Before any product can reach the marketplace, it must overcome a number of obstacles ranging from initial biomarker discovery, through analytical and clinical validation. There is no guarantee these initiative will achieve marketable status. Nonetheless, Cellgen will partner with strong clinical and research partners to ensure we mitigate as much risk as possible before each assay moves to the validation stages.